{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:58:15Z","timestamp":1776329895393,"version":"3.50.1"},"reference-count":42,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:p>Background. In April 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged providers to vaccinate healthy 6- to 23-month-old infants and children with trivalent influenza vaccine (TIV).<\/jats:p><jats:p>Objectives. To describe adverse events (AEs) reported to the Vaccine Adverse Event Reporting System (VAERS) after TIV vaccination among children &amp;lt;2 years of age and to compare reports before the ACIP guideline (January 1990 to June 2002) and after the ACIP guideline (July 2002 to June 2003).<\/jats:p><jats:p>Methods. VAERS is a passive vaccine safety surveillance system begun by the Food and Drug Administration and the Centers for Disease Control and Prevention in 1990. We reviewed reports to VAERS for children &amp;lt;2 years of age who received TIV, alone or in combination with other vaccines. Influenza seasons were defined as the period from July 1 of one year to June 30 of the following year.<\/jats:p><jats:p>Results. Between 1990 and 2003, VAERS received 166 TIV reports for children &amp;lt;2 years of age. There were 62 reports (37%) after administration of TIV alone and 104 reports (63%) after administration of TIV and \u22651 other vaccine. Approximately one third of reports (N = 61) were in the post-ACIP guideline period. The 4 most frequent AE coding terms were fever (N = 59, 35%), unspecified or urticarial rash (42, 25%), seizure (28, 17%), and injection site reaction (28, 17%). The median number of days from vaccination to symptom onset, the percentage of reports that represented serious AEs, and the gender distribution were similar in the pre-ACIP guideline and post-ACIP guideline periods. The percentage of reports describing an underlying medical condition for the subject decreased from 58% before the ACIP guideline to 37% after the ACIP guideline. Nineteen of 28 seizure reports (68%) described fever with the seizure within 2 days after vaccination. Seizure was the most frequent coding term (N = 10, 7 with fever) among 23 serious reports. The annual number of TIV-related VAERS reports for children &amp;lt;2 years of age increased in the post-ACIP guideline period, probably at least in part because of an increase in the number of vaccinees after the ACIP announcement. The safety profiles in the pre-ACIP guideline and post-ACIP guideline periods were similar.<\/jats:p><jats:p>Conclusions. In October 2003, the ACIP recommended that all healthy children 6 to 23 months of age be vaccinated with TIV, starting in the 2004\u20132005 influenza season. This study provides generally reassuring, although limited, data regarding the safety of TIV among children in this age range. Continued surveillance for seizures and other clinically significant AEs is warranted and will continue.<\/jats:p>","DOI":"10.1542\/peds.2004-1519","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T18:18:55Z","timestamp":1107281935000},"page":"453-460","source":"Crossref","is-referenced-by-count":53,"title":["Adverse Events After Inactivated Influenza Vaccination Among Children Less Than 2 Years of Age: Analysis of Reports From the Vaccine Adverse Event Reporting System, 1990\u20132003"],"prefix":"10.1542","volume":"115","author":[{"given":"Ann W.","family":"McMahon","sequence":"first","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Iskander","sequence":"additional","affiliation":[{"name":"Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penina","family":"Haber","sequence":"additional","affiliation":[{"name":"Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soju","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jane","family":"Woo","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Miles","family":"Braun","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ball","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2005,2,1]]},"reference":[{"key":"2021120819192342700_R1","doi-asserted-by":"crossref","unstructured":"Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis.\u20082002;185:147\u2013152","DOI":"10.1086\/338363"},{"key":"2021120819192342700_R2","doi-asserted-by":"crossref","unstructured":"Hurwitz ES, Haber M, Chang A, et al. Studies of the 1996\u20131997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis.\u20082002;182:1218\u20131221","DOI":"10.1086\/315820"},{"key":"2021120819192342700_R3","doi-asserted-by":"crossref","unstructured":"Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J.\u20082001;20:733\u2013740","DOI":"10.1097\/00006454-200108000-00004"},{"key":"2021120819192342700_R4","doi-asserted-by":"crossref","unstructured":"Wise TG, Dolin R, Mazur MH, Top FH, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A\/Victoria\/75-A\/New Jersey\/76 and monovalent B\/Hong Kong\/72 influenza vaccines. J Infect Dis.\u20081977;136(suppl):S507\u2013S517","DOI":"10.1093\/infdis\/136.Supplement_3.S507"},{"key":"2021120819192342700_R5","doi-asserted-by":"crossref","unstructured":"Gwaltney JM, Adams KF, Hendley JO. Acceptability and antigenicity of influenza A\/Victoria\/75 virus vaccines in adults of different ages. J Infect Dis.\u20081977;136(suppl):S491\u2013S495","DOI":"10.1093\/infdis\/136.Supplement_3.S491"},{"key":"2021120819192342700_R6","doi-asserted-by":"crossref","unstructured":"Caplan ES, Hughes TP, O'Donnell S, Levine MM, Hornick RB. Reactogenicity and immunogenicity of parenteral monovalent influenza A\/Victoria\/3\/75 (H3N2) virus vaccine in healthy adults. J Infect Dis.\u20081977;136(suppl):S484\u2013S490","DOI":"10.1093\/infdis\/136.Supplement_3.S484"},{"key":"2021120819192342700_R7","doi-asserted-by":"crossref","unstructured":"Schonberg LB, Bregman DJ, Sullivan an-Boyai JZ, et al. Guillain-Barre\u0301 syndrome following vaccination in the National Influenza Immunization Program: United States, 1976\u20131977. Am J Epidemiol.\u20081979;110:105\u2013123","DOI":"10.1093\/oxfordjournals.aje.a112795"},{"key":"2021120819192342700_R8","doi-asserted-by":"crossref","unstructured":"France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med.\u20082004;158:1031\u20131036","DOI":"10.1001\/archpedi.158.11.1031"},{"key":"2021120819192342700_R9","doi-asserted-by":"crossref","unstructured":"Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J.\u20082004;23:189\u2013197","DOI":"10.1097\/01.inf.0000116292.46143.d6"},{"key":"2021120819192342700_R10","unstructured":"Centers for Disease Control and Prevention. Influenza vaccines, 1983\u20131984. MMWR Morb Mortal Wkly Rep.\u20081983;32:333\u2013337"},{"key":"2021120819192342700_R11","unstructured":"Bridges CB, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep.\u20082002;51(RR-3):1\u201331"},{"key":"2021120819192342700_R12","unstructured":"Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, January\u2013June 2004. MMWR Morb Mortal Wkly Rep.\u20082004;53:Q1\u2013Q4"},{"key":"2021120819192342700_R13","unstructured":"Institute of Medicine. Immunization safety review: influenza and neurological complications. Available at: www.iom.edu\/report.asp?id=15625. Accessed January 2004"},{"key":"2021120819192342700_R14","unstructured":"Code of Federal Regulations. 21 CFR \u00a7600.80. Revised April 1, 2002"},{"key":"2021120819192342700_R15","unstructured":"Centers for Disease Control and Prevention. Overview of vaccine safety. Available at: www.cdc.gov\/nip\/vacsafe\/#NCVIA"},{"key":"2021120819192342700_R16","doi-asserted-by":"crossref","unstructured":"Chen RT, Rastogi SC, Mullen JR. The Vaccine Adverse Event Reporting System (VAERS). Vaccine.\u20081994;12:542\u2013550","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"2021120819192342700_R17","unstructured":"Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep.\u20081997;112:10\u201320"},{"key":"2021120819192342700_R18","doi-asserted-by":"crossref","unstructured":"Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety: information from the Vaccine Adverse Event Reporting System (VAERS). Pediatr Infect Dis J.\u20082004;23:1\u20138","DOI":"10.1097\/00006454-200404000-00002"},{"key":"2021120819192342700_R19","doi-asserted-by":"crossref","unstructured":"Kramarz P, DeStefano F, Gargiullo PM, et al. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Arch Fam Med.\u20082000;9:617\u2013623","DOI":"10.1001\/archfami.9.7.617"},{"key":"2021120819192342700_R20","doi-asserted-by":"crossref","unstructured":"Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med.\u20082001;344:564\u2013572","DOI":"10.1056\/NEJM200102223440804"},{"key":"2021120819192342700_R21","doi-asserted-by":"crossref","unstructured":"Kapikian AZ. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found Symp.\u20082001;238:153\u2013179","DOI":"10.1002\/0470846534.ch10"},{"key":"2021120819192342700_R22","unstructured":"Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep.\u20082003;52:282\u2013284"},{"key":"2021120819192342700_R23","unstructured":"US Census Bureau. United States Census 2000. Available at: www.census.gov\/main\/www\/cen2000.html. Accessed October 2004"},{"key":"2021120819192342700_R24","doi-asserted-by":"crossref","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf.\u20082001;10:483\u2013486","DOI":"10.1002\/pds.677"},{"key":"2021120819192342700_R25","doi-asserted-by":"crossref","unstructured":"Begier ER, Burwen DR, Haber P, Ball R, Vaccine Adverse Event System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis.\u20082004;38:771\u2013779","DOI":"10.1086\/381548"},{"key":"2021120819192342700_R26","doi-asserted-by":"crossref","unstructured":"Zhou W, Pool V, Destefano F, et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS): United States, 1991\u20132001. Pharmacoepidemiol Drug Saf.\u20082004;13:505\u2013510","DOI":"10.1002\/pds.998"},{"key":"2021120819192342700_R27","unstructured":"Centers for Disease Control and Prevention. Childhood influenza-vaccination coverage: United States, 2002\u201303 influenza season. MMWR Morb Mortal Wkly Rep.\u20082004;53:863\u2013866"},{"key":"2021120819192342700_R28","unstructured":"National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel report 2: guidelines for the diagnosis and management of asthma. Available at: www.nhlbi.nih.gov\/guidelines\/asthma\/asthgdln.htm. Accessed October 2004"},{"key":"2021120819192342700_R29","doi-asserted-by":"crossref","unstructured":"Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol.\u20081999;149:981\u2013983","DOI":"10.1093\/oxfordjournals.aje.a009758"},{"key":"2021120819192342700_R30","doi-asserted-by":"crossref","unstructured":"American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med.\u20082001;345:1529\u20131536","DOI":"10.1056\/NEJMoa011961"},{"key":"2021120819192342700_R31","doi-asserted-by":"crossref","unstructured":"Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SHW, Karzon DT. Trials of influenza A\/New Jersey\/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis.\u20081977;136(suppl):S731\u2013S741","DOI":"10.1093\/infdis\/136.Supplement_3.S731"},{"key":"2021120819192342700_R32","doi-asserted-by":"crossref","unstructured":"Daubeney P, Taylor CJ, McGaw J, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin Pract.\u20081997;51:87\u201390","DOI":"10.1111\/j.1742-1241.1997.tb09640.x"},{"key":"2021120819192342700_R33","doi-asserted-by":"crossref","unstructured":"Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health.\u20081995;85:1706\u20131709","DOI":"10.2105\/AJPH.85.12.1706"},{"key":"2021120819192342700_R34","unstructured":"Behrman RE, Kliegman RM, Arvin AM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders; 1996:1691"},{"key":"2021120819192342700_R35","doi-asserted-by":"crossref","unstructured":"Pavlovic MV, Jarebinski MS, Pekmezovic TD, Marjanovic BD, Levic ZM. Febrile convulsions in a Serbian region: a 10-year epidemiological study. Eur J Neurol.\u20081999;6:39\u201342","DOI":"10.1046\/j.1468-1331.1999.610039.x"},{"key":"2021120819192342700_R36","doi-asserted-by":"crossref","unstructured":"Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS, VAERS Working Group. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics.\u20082000;106(4). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/4\/e51","DOI":"10.1542\/peds.106.4.e51"},{"key":"2021120819192342700_R37","doi-asserted-by":"crossref","unstructured":"Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med.\u20082001;345:656\u2013661","DOI":"10.1056\/NEJMoa003077"},{"key":"2021120819192342700_R38","doi-asserted-by":"crossref","unstructured":"Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics.\u20081993;91:1158\u20131165","DOI":"10.1542\/peds.91.6.1158"},{"key":"2021120819192342700_R39","doi-asserted-by":"crossref","unstructured":"Gale JL, Thapa PB, Wassilak SG, Bobo JK, Mendelman PM, Foy HM. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control study. JAMA.\u20081994;271:37\u201341","DOI":"10.1001\/jama.271.1.37"},{"key":"2021120819192342700_R40","doi-asserted-by":"crossref","unstructured":"Ellenberg JH, Hirtz DG, Nelson KB. Age at onset of seizures in young children. Ann Neurol.\u20081984;15:127\u2013134","DOI":"10.1002\/ana.410150204"},{"key":"2021120819192342700_R41","unstructured":"Harper SA, Fukuda K, Uyeki K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082004;53(RR-6):1\u201340"},{"key":"2021120819192342700_R42","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics.\u20082004;113:1441\u20131447","DOI":"10.1542\/peds.113.5.1441"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/2\/453\/1005687\/zpe00205000453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/2\/453\/1005687\/zpe00205000453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T23:04:39Z","timestamp":1682982279000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/2\/453\/67386\/Adverse-Events-After-Inactivated-Influenza"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2,1]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-1519","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}